Overview

Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Normal Renal Function and Severe Renal Impairment

Status:
Completed

Trial end date:
2014-06-09

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to evaluate the single-dose pharmacokinetics (PK) of velpatasvir (formerly GS-5816) in participants with severe renal impairment using matched healthy participants as a control group.

Phase:

Phase 1

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Velpatasvir